CD70 expression in tumor-associated fibroblasts predicts worse survival in colorectal cancer patients
The anticancer effects of immune checkpoint inhibitors against CTLA4 and CD274-PDCD1 axes are evident. However, these immunotherapies for colorectal cancers (CRCs) are now limited to a small subset of patients with microsatellite unstable tumors. Thus, therapeutics targeting other types of CRCs is desired. The CD70–CD27 axis plays a co-stimulatory role in promoting the expansion and differentiation of T-lymphocytes through the activation of NFκB pathway. Aberrant activation of the CD70–CD27 axis accelerates tumor cell proliferation, survival, and immune evasion of tumor cells. Based on these observations, drugs modulating the CD70–CD27 axis have been developed with expectation of anticancer effects. In the present study, 269 primary CRCs were evaluated immunohistochemically for CD70, CD27, and FOXP3 expression to assess their clinical usage and the application of CD70–CD27 axis modulating drugs. CRC tumor cells rarely (2.2%) expressed CD70. In contrast, tumor-surrounding fibroblasts showed various CD70 expressions (fCD70) in 14.9%. The logistic regression analysis revealed significant association of fCD70 expression with incomplete resection status (OR, 2.60; 95% CI, 1.10–6.13; P = 0.029). Overall survival was significantly decreased in the cohort of the patients with fCD70-positive tumor (P = 0.0078). Furthermore, significantly more CD27+ tumor-associated lymphocytes were detected within the primary CRCs without metastases (P = 0.024). Thus, the CD70–CD27 axis may have several roles in CRCs independent from their mismatch repair (MMR) system status. CD70–CD27 pathway-modulating therapies may be applied to CRC patients regardless of their tumor MMR status.
KeywordsColorectal cancer (CRC) Immunohistochemistry CD70 CD27 FOXP3
We thank Dr. Yutaka Kondo (Nagoya University) and Dr. Yoshitaka Sekido (Aichi Cancer Center Research Institute) for SW48 and ACC-MESO-1 cells, respectively. We also thank Ms. Kazuko Tanimizu, Mr. Naoki Igari, and Mr. Motoyasu Takeuchi (Aichi Medical University) for their assistance on tissue preparation and immunohistochemical staining. We had the support on the manuscript editing from Ms. Yukiko Kuru (Aichi Medical University).
Shingo Inaguma: conceived, designed, and supervised the overall study; Satoshi Inoue, Shingo Inaguma: performed molecular experiments, histological and statistical analyses, made the figures and tables, and wrote the manuscript; Hideaki Ito, Takumi Tsunoda, Hideki Murakami: performed immunohistochemical staining; Satoshi Inoue, Masahide Ebi, Naotaka Ogasawara: collected and analyzed the clinical data; Kunio Kasugai, Kenji Kasai, Hiroshi Ikeda: critically reviewed the manuscript. All authors have read and gave final approval to the submitted version.
This work was supported as a part of Grant-in-Aid for Scientific Research (C) (to Shingo Inaguma, 17K08706).
Compliance with ethical standards
This project was approved by the Institutional Ethical Review Board of Aichi Medical University Hospital.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Callahan MK, Postow MA, Wolchok JD (2014) CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol 4:385Google Scholar
- 9.Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF (2006) Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 66:2328–2337CrossRefGoogle Scholar
- 10.Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz JB, Ohgaki H, Aguzzi A, Rammensee HG, Weller M (2002) Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 62:2592–2599Google Scholar
- 11.Ranheim EA, Cantwell MJ, Kipps TJ (1995) Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 85:3556–3565Google Scholar
- 12.Bertrand P, Maingonnat C, Penther D, Guney S, Ruminy P, Picquenot JM, Mareschal S, Alcantara M, Bouzelfen A, Dubois S, Figeac M, Bastard C, Tilly H, Jardin F (2013) The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma. Genes Chromosom Cancer 52:764–774CrossRefGoogle Scholar
- 21.Inaguma S, Lasota J, Felisiak-Golabek A, Kowalik A, Wang Z, Zieba S, Kalisz J, Ikeda H, Miettinen M (2017) Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: possible roles of tumour micro environmental factors for CD274 expression. J Pathol Clin Res 3:268–278CrossRefGoogle Scholar
- 24.Jacobs J, Deschoolmeester V, Zwaenepoel K, Flieswasser T, Deben C, van den Bossche J, Hermans C, Rolfo C, Peeters M, de Wever O, Lardon F, Siozopoulou V, Smits E, Pauwels P (2018) Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. Oncoimmunology 7:e1440167CrossRefGoogle Scholar
- 27.Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SME, Saunders M, Wajant H, Brouckaert P, Huyghe L, van Hauwermeiren T, Thibault A, de Haard HJ (2014) ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. MAbs 6:523–532CrossRefGoogle Scholar
- 28.Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, de Vos S, Hamlin PA, Kim SK, Whiting NC, Gartner EM, Zhao B, Thompson JA (2014) Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Investig New Drugs 32:1246–1257CrossRefGoogle Scholar